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6-Formylindolo[3,2-b]carbazole (FICZ) is a potent aryl hydrocarbon receptor (AHR) agonist that is effi-
ciently metabolized by AHR-regulated cytochrome P4501 enzymes. FICZ is a proposed physiological
AHR ligand that induces its own degradation as part of a regulatory negative feedback loop. In vitro stud-
ies in cells show that CYP1 inhibition in the presence of FICZ results in enhanced AHR activation, suggest-
ing that FICZ accumulates in the cell when its metabolism is blocked. We used zebrafish (Danio rerio)
embryos to investigate the in vivo effects of FICZ when CYP1A is knocked down or inhibited. Embryos
were injected with morpholino antisense oligonucleotides targeting CYP1A (CYP1A-MO), Ahr2, or a com-
bination of both. FICZ exposure of non-injected embryos or embryos injected with control morpholino
had little effect. In CYP1A-MO-injected embryos, however, FICZ dramatically increased mortality, inci-
dence and severity of pericardial edema and circulation failure, reduced hatching frequency, blocked
swim bladder inflation, and strongly potentiated expression of Ahr2-regulated genes. These effects were
substantially reduced in embryos with a combined knockdown of Ahr2 and CYP1A, indicating that the
toxicity was mediated at least partly by Ahr2. Co-exposure to the CYP1 inhibitor alpha-naphthoflavone
(aNF) and FICZ had similar effects as the combination of CYP1A-MO and FICZ. HPLC analysis of FICZ-
exposed embryos showed increased levels of FICZ after concomitant CYP1A-MO injection or aNF co-
exposure. Together, these results show that a functioning CYP1/AHR feedback loop is crucial for regula-
tion of AHR signaling by a potential physiological ligand in vivo and further highlights the role of CYP1
enzymes in regulating biological effects of FICZ.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The aryl hydrocarbon receptor (AHR) is a ligand-activated tran-
scription factor that regulates expression of many genes including
those for the cytochrome P450 family 1 (CYP1; CYP1A, CYP1B, and
CYP1C) enzymes. Both AHR itself and the CYP1 enzymes have beenhighly conserved during vertebrate evolution [1,2], suggesting that
these systems have conserved physiological functions. This is fur-
ther corroborated by the presence of AHR in most cell types and
during most phases of development [3,4]. Numerous reports sug-
gest the existence of physiological AHR agonist(s) and suggest that
AHR-induced CYP1 activity is important for down-regulating AHR
activity by metabolically depleting the agonist, generating a tightly
regulated negative feedback loop of receptor signaling. In support
of this suggestion, mutant cells lacking functional CYP1A1 enzyme
activity and CYP1 triple knockout mice (cyp1a1/1a2/1b1/) show
elevated AHR activation and CYP1 transcription [5–13]. Together
these data suggest that CYP1-inhibiting agents may disrupt physi-
ological AHR signaling by interfering with CYP1/AHR feedback
regulation, causing accumulation of endogenous agonist(s) and
thus a subsequent prolonged and/or potentiated AHR activation.
The endogenous and proposed physiological AHR ligand
6-formylindolo[3,2-b]carbazole (FICZ) is a high-potency AHR
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malian CYP1 enzymes, resulting in efficient auto-regulatory feed-
back of its action and thereby only transient activation of AHR
signaling in cell systems [14]. Such transient activation, in contrast
to sustained activation by the highly toxic persistent pollutant 2,
3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), may be essential for
physiological AHR signaling [15]. The ability of FICZ to activate
AHR signaling appears to be evolutionarily conserved. FICZ has
been shown to bind and activate AHRs in different vertebrate spe-
cies in addition to human, including mouse, African clawed frog
(Xenopus laevis), zebrafish (Danio rerio) and several avian species
[16–20]. Furthermore, recent studies suggest that FICZ–AHR and
TCDD–AHR interactions are distinct. For example, avian species
known to differ in response to TCDD show no significant differ-
ences in sensitivity to FICZ [20], and FICZ differs from TCDD in its
ability to bind AHR variants with certain mutated amino acids in
the ligand-binding domain [21]. Such results emphasize the
robustness of the FICZ–AHR interaction and further suggest that
FICZ could have a role as an important natural signaling molecule.
Previously, we described how various agents inhibiting the cat-
alytic activity of CYP1A1 enzymes may generate prolonged and
potentiated AHR activation in a human cell line in vitro, by compro-
mising the cellular clearance of FICZ [14,22,23]. In line with these
reports, a recent paper by Jönsson et al. [19] demonstrated an
increased AHR activation and enhanced toxicity in chicken
embryos after co-exposure to FICZ and ketoconazole, a known inhi-
bitor of CYP1 enzyme activity. However, ketoconazole can inhibit
many CYPs, and those studies did not determine whether the
observed toxicity was dependent on the AHR; this is a primary
aim of the current study. Considering the crucial role of CYP1
enzymes in regulating AHR activation by FICZ in vitro, we hypoth-
esized that the otherwise non-toxic AHR agonist FICZ may cause
AHR-dependent toxicity if its metabolic clearance is blocked. To
address this, we studied FICZ-mediated phenotypic and transcrip-
tional effects of CYP1A loss of function in zebrafish embryos using
morpholino-mediated knockdown of CYP1A (CYP1A-MO), Ahr2
(Ahr2-MO), or combined knockdown of CYP1A and Ahr2 (CYP1A/
Ahr2-MO). Alpha-naphthoflavone (aNF), a potent CYP1 inhibitor
with IC50 values in the nM range for human CYP1 enzymes [24],
was used to investigate effects of chemical inhibition of CYP1.
aNF is also considered a weak AHR agonist and partial AHR antag-
onist [25–28]. Our results show that a functioning CYP1/AHR feed-
back loop is crucial for regulating biological effects of FICZ in
zebrafish embryos in vivo and further support the hypothesis that
CYP1 enzymes function to regulate endogenous AHR ligands and
receptor activity.2. Material and methods
2.1. Chemicals
Dimethyl sulfoxide (DMSO) was obtained from Acros Organics
(Thermo Fisher Scientific, Pittsburgh, PA, USA) and Sigma–Aldrich
(Stockholm, Sweden). FICZ (P95%) was obtained from Enzo Life
Sciences (Farmingdale, NY, USA) and Syntastic AB (Stockholm,
Sweden), and aNF (P98%) was from Sigma–Aldrich (Stockholm,
Sweden). Acetonitrile (VWR, Stockholm Sweden) and formic acid
(Sigma–Aldrich, Stockholm, Sweden) were of HPLC grade.2.2. Zebrafish breeding
Zebrafish were maintained under standard light and tempera-
ture conditions: 14 h of light, 10 h of dark, at 28.5 C, with water
quality monitored daily. Experiments were performed at two
different locations; Woods Hole Oceanographic Institution(morpholino studies) and Karolinska Institutet (aNF studies); hence,
zebrafish with two different origins were used. However, exposure
regimens were constant throughout all experiments and non-
fertilized eggs were removed within the first 10 h in both settings.
Fish embryos that have hatched but not started feeding are techni-
cally eleutheroembryos, but for simplicity, in this paper we refer to
zebrafish at all stages before 6 dpf as embryos.
2.2.1. Morpholino (MO) studies
For all CYP1A-MO and Ahr2-MO experiments zebrafish from the
Tupfel/long fin (TL) mutation wild-type strain were used. Embryos
were collected from group matings of at least 30 females and 15
males per tank, and several tanks were used during each breeding
event. Eggs were maintained in 0.3 Danieau’s solution (17 mM
NaCl, 2 mM KCl, 0.12 mM MgSO4, 1.8 mM Ca(NO3)2, and 1.5 mM
HEPES buffer).
2.2.2. aNF studies
All experiments with aNF ± FICZ were performed using zebra-
fish from the AB wild type strain. Embryos were collected from
group matings of 3 females and 3 males per tank, and only one
tank was used during each breeding event. Eggs were maintained
in E3 embryo medium (5.0 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2,
and 0.33 mM MgSO4).
2.3. Morpholino mediated knockdown
Zebrafish embryos were injected with morpholino antisense
oligonucleotides blocking CYP1A or Ahr2 translation, or with a
combination of both morpholinos, at the 1–4 cell stage as previ-
ously described [29]. Morpholinos targeting the transcriptional
start site of CYP1A (CYP1A-MO; 5-TGGATACTTTCCAGTTCTCA
GCTCT-3) [30] or Ahr2 (Ahr2-MO; 5-TGTACCGATACCCGCCGACAT
GGTT-3) [31] and control morpholinos (Ctrl-MO; 5-CCTCTTACC
TCAGTTACAATTTATA-3) were obtained from Gene Tools (Philo-
math, OR, USA). The morpholinos were diluted in sterile-filtered
deionized water to 0.15 mM (CYP1A-MO), 0.18 mM (Ahr2-MO),
and 0.15/0.18 mM (Ctrl-MO), respectively. For injection of the
combination of CYP1A-MO and Ahr2-MO morpholinos with twice
the concentration was prepared. A Narishige IM-300 microinjector
(Narishige, Tokyo, Japan) with a fine glass needle was used to inject
3–5 nl of morpholinos into the yolk of the embryos. All morpholi-
nos were fluorescein-tagged and embryos were screened at 6–
8 hpf by fluorescence microscopy to verify successful incorpora-
tion. Any damaged embryos or those not displaying homogenous
fluorescence were removed. In addition to the MO-injected groups,
groups of non-injected (NI) embryos were used.
2.4. Exposure and sampling
All exposures were initiated at 24 h post fertilization and per-
formed in glass Petri dishes. Groups of embryos, with or without
concomitant morpholino treatment, were exposed to various con-
centrations of FICZ (0.001–100 nM), aNF (0.1–2.5 lM), combina-
tions of FICZ and aNF, or corresponding amount of vehicle (0.01%
DMSO, v/v) at a density of 1 embryo/ml Danieau’s solution (0.3)
or E3 medium. Exposures were started by adding the compound
directly into the water at a position distant from the eggs and then
immediately mixed through gentle but thorough swirling and the
embryos were kept in the same exposure medium throughout
the experiment. An additional experiment where the exposure
medium was replenished every 8 h was included for comparison.
For morphological assessment, embryos were scored for edema
and circulation failure using a stereomicroscope as described
below. Samples for quantitative real time PCR (qRT-PCR) analysis
were collected as group replicates composed of 7–10 pooled
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Inc., Austin, TX, USA) at 4 C for up to a week then at 20 C until
RNA extraction. Samples for chemical analysis using high perfor-
mance liquid chromatography (HPLC) were collected as group
replicates of 10 pooled embryos in 1.5 ml centrifuge tubes and
washed once with clean E3 medium. The E3 mediumwas aspirated
and the samples were stored at 20 C until extraction and
analysis.
2.5. Morphological assessment
Dead embryos were counted and discarded every day, and
cumulative mortality was calculated at 2 or 3 days post treatment
(dpt).
2.5.1. Morpholino experiments
At 1–3 dpt embryos were examined for phenotypic effects using
a Zeiss Stemi 2000-CS microscope (Zeiss, Thornwood, NY, USA).
Severity of pericardial edema and circulatory failure was deter-
mined at 2 or 3 dpt (3 or 4 dpf), and hatching frequency and swim
bladder inflation were determined at 3 dpt. Severity of pericardial
edema and circulatory failure was scored between 0–3 with ‘‘0”
being no effect and ‘‘3” being a severe effect (see Fig. 1D). Severity
of circulatory failure is defined as different degrees of reduced
heart rate and circulation of blood cells through the trunk vessels.
Frequency of hatching, swim bladder inflation and mortality were
determined as the percentage of embryos showing those effects
compared to the total number at exposure start. For the dose–re-
sponse study (Fig. 3) exposure vessels were randomized in order
to avoid subjective scoring.
2.5.2. aNF experiments
At 3 dpt (4 dpf) embryos were sedated using tricaine (150 mg/
ml; Sigma–Aldrich, Stockholm, Sweden), photographed using a
Leica MZ16F microscope and Leica Application Suite V4.1. (Leica,
Stockholm, Sweden) and scored for incidence of pericardial and/
or yolk sac edema and swim bladder inflation. The incidence of
edema and swim bladder inflation was determined as the percent-
age of embryos showing those effects compared to the total num-
ber at exposure start. Other effects such as craniofacial
malformations, tube-shaped heart and reduced body length were
noted but not scored.
2.6. RNA purification and quantitative real time RT-PCR
Total RNA was isolated using the AurumTM Total RNA Fatty and
Fibrous Tissue kit followed by cDNA synthesis using the iScript
cDNA Synthesis kit, both from Bio-Rad (Stockholm, Sweden),
according to the manufacturer’s instructions. The concentration
and quality of RNA was determined spectrophotometrically using
a NanoDrop 1000 (Thermo Scientific, Stockholm, Sweden). Quan-
tification of gene expression was performed using Power SYBR
Green qPCR Master Mix (Thermo Fisher Scientific, Stockholm, Swe-
den) with detection on an Applied Biosystems 7500 Real-Time PCR
system (Thermo Fischer Scientific, Stockholm, Sweden). Relative
gene expression quantification was based on the comparative
threshold cycle method (2DDCt). rpl13 (referred to as l13 through-
out this study) was chosen as reference gene based on comparisons
of temporal- and exposure-dependent effects on expression of
commonly used housekeeping genes (not shown). Quantitative
real-time PCR (qRT-PCR) analysis was performed with the follow-
ing protocol: 95 C for 10 min, followed by 35–40 cycles of 95 C
for 15 s and 62 C for 45 s. Melt curve analysis was performed at
the end of each PCR run to ensure that a single product was ampli-
fied. Gene-specific primers for qRT-PCR were synthesized bySigma–Aldrich (Stockholm, Sweden) and sequences for the gene-
specific primers are given in Table 1.2.7. Extraction and quantification of FICZ
Deionized sterile water (200 ll) was added to each sample and
they were then homogenized by sonication on ice (4  5 s) using a
MSE Soniprep 150 equipped with an exponential probe (Measuring
and Scientific Equipment, London, UK). The embryo homogenates
were extracted by adding acetonitrile (300 ll) and vortexing each
sample tube for 20 s followed by centrifugation at 13,000 rpm for
15 min at 4 C. Chemical analysis of the supernatants was per-
formed using an YL9100 HPLC system equipped with an Agilent
1200 fluorescence detector (both from Dalco ChromTech, Stock-
holm, Sweden). Separations were achieved on a 150-mm long,
5 lm particle size reverse phase ACE C18-AR column (Scantec
Lab, Partille, Sweden) using a 25-min linear mobile phase gradient
from 40% B to 100% B (A, 1.5 mM formic acid in H2O; B, 1.5 mM
formic acid in acetonitrile) at a flow rate of 0.8 ml/min. The fluores-
cence of FICZ was determined at excitation/emission wavelengths
of 390/525 nm and quantified according to a standard curve of
FICZ.2.8. Statistics
Statistical analysis was performed using Prism 5 from GraphPad
Software Inc. (La Jolla, CA, USA). For determining effects on the
rates of mortality, hatching, swim bladder inflation, pericardial
edema, and circulatory failure we used Fisher’s exact test and, to
control family wise error rate at multiple comparisons, Holm–
Bonferroni’s method was used [32]. The statistical methods used
to determine effects on mRNA expression were Student’s t test or
one-way ANOVA followed by Tukey’s or Dunnett’s post hoc tests.
Data were log-transformed when variance differed. Values for
LC50 of FICZ in the presence of aNF were calculated using the curve
fitting routine of GraphPad Prism for nonlinear regression
sigmoidal dose–response. Statistical significance of more than
additive effects on mRNA expression was determined using
Student’s t test followed by Holm–Sidak post hoc test. For this anal-
ysis, calculated levels of CYP1A expression, i.e. the sum of the single
exposures (FICZ alone + aNF alone), was compared to the observed
levels of CYP1A expression after co-exposure to FICZ + aNF. The
statistical tests used are also given in the figure legends.3. Results
3.1. Impact of CYP1A knockdown on FICZ-mediated effects in zebrafish
embryos
In order to determine the role of the CYP1A enzyme in regulat-
ing FICZ-mediated activities, various endpoints were examined in
groups of zebrafish embryos injected with a morpholino targeting
CYP1A (CYP1A-MO) and exposed to FICZ (10 or 100 nM) or vehicle
(DMSO, 0.01%). Embryos injected with control morpholino (Ctrl-
MO) and non-injected embryos (NI) were similarly exposed and
included for comparison. Mortality and phenotypic effects were
determined at 3 dpt (4 dpf) (Fig. 1), while effects on transcription
were examined at 6, 24, and 48 hpt (Fig 2). Because FICZ is rapidly
cleared in mammalian cells, we performed an additional experi-
ment in which the exposure medium containing FICZ (100 nM)
or DMSO was replenished every 8 h up to 6 dpf, with the purpose
of mimicking persistent FICZ exposure and to determine whether
this might elicit mortality and phenotypic effects.
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Fig. 1. Impact of CYP1A knockdown on FICZ-mediated effects on mortality and phenotype. Groups of embryos, non-injected (NI) or injected with Ctrl-MO (Ctrl) or CYP1A-MO
(CYP), were exposed to vehicle control (DMSO; D), or 10 or 100 nM FICZ (F10, F100). All endpoints were determined at 3 dpt (4 dpf); (A) cumulative mortality, (B) hatching
rates, (C) swim bladder inflation and (E) rates of pericardial edema and circulatory failure. Severity of pericardial edema and circulatory failure was graded 0–3, ‘‘0”
representing no effect and ‘‘1–3” representing effects of increasing severity. The severity scoring index for pericardial edema is shown in (D). In (B), (C) and (E) the hatched
part of a bar indicates the mortality rate. Results are shown as% of total number of embryos at exposure start based on three separate experiments (n = 69–99). Statistically
significant differences in numbers of affected and unaffected embryos between the MO injected groups (Ctrl or CYP) and the corresponding NI group were determined by
Fisher’s exact test with Bonferroni’s correction and are shown by asterisks (⁄⁄p < 0.01 and ⁄⁄⁄p < 0.001). For the statistical analysis of data in (E) ‘‘affected embryos” are
represented by the pooled number of all living embryos with severity score 1–3 in a group.
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CYP1A morphants exposed to FICZ exhibited increased inci-
dence of mortality (Fig. 1A), non-hatching (Fig. 1B), failure of swim
bladder inflation (Fig. 1C), and increased severity of pericardial
edema and circulation failure (Fig. 1E) compared to FICZ-exposed
NI or Ctrl-MO-injected embryos. The range of severity scores of
edema is illustrated in Fig. 1D. Increased toxicity was observed
with both concentrations of FICZ, although FICZ at the highest con-
centration had the strongest effect (32% and 54% mortality for 10
and 100 nM FICZ, respectively). Embryos exposed to FICZ in the
Ctrl-MO and NI groups displayed no significant incidence of anyof the measured endpoints compared with the control groups
and no significant difference was observed between similarly
exposed Ctrl-MO and NI embryos. Embryos for which the FICZ con-
taining medium was replenished every 8 h appeared normal at
6 dpf (data not shown). CYP1A-MO embryos exposed to vehicle
alone displayed a small but statistically significant increase in
toxicity (Fig. 1A–E).
3.1.2. Transcriptional effects
Knowing that FICZ is a potent activator of Ahr2 in zebrafish [16]
and an excellent substrate for human and rat CYP1 enzymes
Table 1
Zebrafish specific primer sequences used in the study.
Gene Sequence
zfCYP1A1 F: 50-GCATTACGATACGTTCGATAAGGAC
R: 50-GCTCCGAATAGGTCATTGACGAT
zfCYP1C1 F: 50-AGTGGCACAGTCTACTTTGAGAG
R: 50-TCGTCCATCAGCACTCAG
zfCYP1C2 F: 50-GTGGTGGAGCACAGACTAAG
R: 50-TTCAGTATGAGCCTCAGTCAAAC
zfAHRRA F: 50-AGAACCAGCAGGACACACCA
R: 50-TGGTGGAAGCCCAGGTAATCA
zfAHRRB F: 50-AGGACACTGATGAGGATGTTGTG
R: 50-GTAAGAAACGGAGTCAATTCAGGAG
zfL13 F: 50-GCTAAGGACGGAGTGAACAAC
R: 50-GCACTCTCTTCTGCCAGTC
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sure of CYP1A-MO-injected embryos to FICZ was reflected in pro-
longed or potentiated Ahr2 activation. Induction of CYP1A mRNA
was chosen as a marker for Ahr2 transactivation. Exposure of
Ctrl-MO-injected and NI embryos to FICZ (100 nM) resulted in
CYP1A induction as expected (Fig. 2A) and the two groups showed
no difference in induction level (not shown). However, CYP1A-MO-
injected embryos showed a strongly increased CYP1A induction by
FICZ compared to Ctrl-MO-injected embryos that were exposed toDMSO
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Fig. 2. Impact of CYP1A knockdown on FICZ-mediated transcriptional effects. Groups o
vehicle control (DMSO) or 100 nM FICZ. Effects on expression of Ahr2-related genes were
Ahrrb. Relative transcription was calculated using l13 as a reference gene and data from
significant differences in levels of transcription between paired groups of embryos inject
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graphs.FICZ at all time-points (5.0-, 4.5-, and 4.0-fold at 6, 24, and 48 hpt,
respectively; Fig. 2A). Other AhR2 regulated genes (CYP1C1,
CYP1C2, Ahrra, and Ahrrb) were also strongly induced by FICZ in
the CYP1A-MO groups but not in the Ctrl-MO groups, with CYP1C1
and Ahrra showing the strongest induction (Fig. 2B and C). CYP1A
knockdown and exposure to vehicle alone resulted in a statistically
significant increase in CYP1A expression at all time-points (29-,
15-, and 15-fold higher expression compared to Ctrl-MO injected
embryos at 6, 24, and 48 hpt, respectively). A similar trend was
observed for Ahrra expression.
3.2. Dose-dependent effects of FICZ
Due to the high toxicity observed in CYP1A-MO-injected
embryos exposed to 10 or 100 nM FICZ, we next set out to deter-
mine the lowest concentration of FICZ able to cause toxicity and
AHR-related transcriptional responses in these morphants. Zebra-
fish embryos injected with CYP1A-MO were exposed to a wide
range of FICZ concentrations (0.01–10 nM) or vehicle (DMSO,
0.01%). Similarly exposed embryos injected with Ctrl-MO or not
injected (NI) were included for comparison. Mortality and effects
on pericardial edema and circulatory function were examined at
48 hpt (3 dpf), while effects on CYP1A transcription were examined
between 6 and 48 hpt (Fig 3).Ctrl MO
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(C). Data in (A) and (B) are shown as% of total number of embryos at exposure start based on three separate experiments (n = 75–105) and statistically significant differences
were determined by Fisher’s exact test with Bonferroni’s correction. Asterisks indicate differences between DMSO control and FICZ-exposed groups of CYP1A-MO injected
embryos (⁄⁄⁄p < 0.001). Daggers designate differences between the Ctrl-MO and CYP1A-MO injected groups at the same FICZ concentration (yp < 0.05, yyp < 0.01, and
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time-point as calibrators. Differences in transcription between Ctrl-MO and CYP1A-MO injected groups at the same FICZ concentration were determined using One-way
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Footnote: 1)These groups were not statistically analyzed since n = 2 in the Ctrl-MO groups.
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In CYP1A-MO-injected embryos exposure to 1 or 10 nM FICZ
gave a higher mortality rate than exposure to DMSO (Fig. 3A). With
exposure of CYP1A MO-injected embryos to vehicle alone there
was a small tendency (but not statistically significant) for an
increase in mortality (Fig. 3A). For incidence of pericardial edema
and circulatory failure in the CYP1-MO-injected embryos, there
were no significant differences between the FICZ-exposed groups
and the vehicle control (DMSO) (Fig. 3B and C). For the same end-
points, all CYP1A MO-injected embryos, e.g. both the DMSO-
exposed and FICZ-exposed groups, showed a significant increase
compared to exposed Ctrl-MO-injected embryos (Fig. 3B and C).
Results with NI embryos did not differ significantly from those in
embryos injected with Ctrl-MO (not shown).
3.2.2. Transcriptional effects
CYP1A-MO-injection resulted in an increase in CYP1A expres-
sion in all FICZ-exposed groups and the DMSO-exposed group at
all time-points tested compared to the corresponding Ctrl-MO-
injected group (Fig. 3C). However, the effect of FICZ was substan-
tially reduced at 48 hpf.3.3. AHR2-dependent effects of FICZ
The increase in transcriptional responses in parallel with the
increased toxicity resulting from FICZ with CYP1A-MO led us to
ask whether the toxic effects were AHR2-dependent. Zebrafish
embryos injected with the CYP1A-MO, AHR2-MO, or a combination
of CYP1A-MO and AHR2-MO were exposed to FICZ (10 nM) or
vehicle (DMSO, 0.01%). Similarly exposed embryos injected with
Ctrl-MO and NI embryos were included for comparison. Mortality,
incidences of pericardial edema and circulatory failure were
examined at 2 dpt (3 dpf) (Fig. 4A and B), and effects on CYP1A
transcription were examined at 6, 24, and 48 hpt (Fig 4C).
3.3.1. Mortality and phenotypic effects
Exposure to FICZ had no impact on the phenotype in embryos
injected with Ahr2-MO or Ctrl-MO alone (Fig. 4A and B). In agree-
ment with results in the other experiments (shown in Figs. 1 and
3), CYP1A-MO-injected embryos exposed to 10 nM FICZ showed a
significant increase in mortality (Fig. 4A) and pericardial edema
and circulatory failure (Fig. 4B) as compared to FICZ-exposed
embryos injected with Ctrl-MO. Co-injection of Ahr2-MO
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were determined by One-way ANOVA followed by Tukey’s post hoc test and are indicated by different letters (p < 0.05).
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cardial edema and circulatory failure seen in FICZ-exposed,
CYP1A-MO-injected embryos (Fig. 4B). The group co-injected with
Ahr2-MO and CYP1A-MO and exposed to FICZ also showed a ten-
dency for reduction of mortality from 48% (CYP1A-MO, FICZ) to
29% (AHR2-MO + CYP1A-MO, FICZ), but this was not statistically
significant. The CYP1A-MO injected DMSO-exposed group dis-
played a slight but significantly higher incidence of circulatory fail-
ure compared with the Ctrl-MO injected DMSO group; this was not
observed in the combined CYP1A/Ahr2-MO-injection group.
Results with NI embryos did not differ significantly from those
with Ctrl-MO-injected embryos and thus are not included in the
figure.3.3.2. Transcriptional effects
In the Ctrl-MO groups, exposure to 10 nM FICZ generated a 36-,
30-, and 9-fold induction of CYP1A at 6, 24, and 48 hpt, respec-
tively, while FICZ exposure of Ahr2-MO embryos resulted in a
lower CYP1A induction at 6 and 24 hpt and a somewhat higher
induction at 48 hpt than in the Ctrl-MO group (Fig. 4C). In
CYP1A-MO groups, CYP1A induction by FICZ was strongly
enhanced relative to the levels in the Ctrl-MO groups at all time-
points, reaching levels of 168-, 134-, and 35-fold the DMSO-
exposed, Ctrl-MO-injected control values at 6, 24, and 48 hpt,
respectively (and 4.7-, 4.7-, and 3.9-fold as compared to the FICZ-
exposed, Ctrl-MO-injected control values at 6, 24, and 48 hpt,
respectively).
124 E. Wincent et al. / Biochemical Pharmacology 110–111 (2016) 117–129Most importantly, the level of CYP1A induction by FICZ in the
Ahr2-MO and CYP1A-MO co-injected group was greatly reduced
as compared to the FICZ-exposed CYP1A-MO-injected embryos at
6 and 24 hpt, although by 48 hpt this effect was not seen. Ahr2-
MO-injected embryos exposed to DMSO showed no difference in
CYP1A expression at 6 hpt compared to Ctrl-MO-injected embryos.
The same morpholino treatment and DMSO exposure resulted in a
lower level of CYP1A transcript at 24 hpt, while a tendency for
increase (4-fold but not significant) was observed at 48 hpt
(Fig. 4C). Knock-down of CYP1A resulted in a significant induction
of CYP1A expression at all time-points in the vehicle control group.
At 6 and 24 hpt, the level of CYP1A expression in the vehicle control
was lower in embryos co-injected with Ahr2-MO and CYP1A-MO
as compared to those injected with CYP1A-MO alone. At 48 hpt
there was a trend for higher CYP1A expression in co-injectedFig. 5. Phenotypic and quantitated effects of FICZ and aNF alone and in combination. G
(DMSO) in combination with aNF starting at 1 dpf. (A) and(B) Illustrative pictures of ph
+ aNF (0.5 lM) (bottom). (B) Embryo treated with FICZ (0.005 nM) + aNF (1.0 lM). Abbr
reduced eye size (RE), pericardial- and yolk sac edema (PE, YSE), and tube-shaped heart
and phenotypic effects after exposure to (C) FICZ (0.005–10 nM; F0.005 etc), or (D) aNF (0
Ahr2-MO (Ahr) were exposed to FICZ (10 nM), aNF (1 lM), or a combination of FICZ an
frequencies of cumulative mortality (Dead), pericardial- or yolk sac edema (Edema), an
number of embryos at exposure start based on one representative experiment (n = 25
significant differences among groups were determined by Fisher’s exact test with Bonfe
⁄⁄⁄p < 0.001) between a treatment group and the reference group (D, A1, A0.5, or Ahr + D)
injected group. For embryo groups where no significant mortality was observed, the dif
indicated by double daggers (p < 0.05; p < 0.001).embryos compared to embryos injected with CYP1A-MO alone,
but this was not statistically significant.
3.4. Combined exposures of zebrafish embryos to FICZ and aNF
To test whether a chemical CYP1 inhibitor could mimic the
effects observed with the morpholino-mediated CYP1A knock-
down, we performed a series of experiments exposing zebrafish
embryos to the CYP1A inhibitor aNF (0.1–2.5 lM) and FICZ
(0.001–10 nM) separately or in combination. DMSO (0.01%) was
used as the vehicle control. Embryos were exposed from 24 hpf
and incidences of mortality, edemas and non-inflated swim blad-
der were examined at 3 dpt (4 dpf). Typical phenotypic effects
observed with the different exposures and statistical analyses of
these effects are shown in Fig. 5. The impact on CYP1A transcriptionroups of 1 dpf embryos were exposed to different doses of FICZ or vehicle control
enotypic effects; (A) control embryo (top) and embryo treated with FICZ (1.0 nM)
eviations: reduced growth (RG), body curvature (BC), craniofacial deformities (CD),
(TSH). All pictures were taken at 3 dpt (4 dpf). (C)–(F) quantitated data on lethality
.1 to 1 lM; A0.1 etc), or (E) combinations of aNF and FICZ. (F) Embryos injected with
d aNF. DMSO (D) was used as a vehicle control for all exposures. At 3 dpt (4 dpf)
d failure of swim-bladder inflation (-SB, no edema) were determined as% of total
–30). Embryos with none of the effects listed were scored as normal. Statistically
rroni’s correction. A difference in mortality rate is indicated by asterisks (⁄⁄p < 0.01;
and by daggers (yyyp < 0.001) between an Ahr2-MO group and its corresponding non-
ference in rates of any effect between an exposed group and the reference group is
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Fig. 6. Effects of aNF on FICZ-mediated CYP1A transcription and role of Ahr2. Groups of 1-dpf embryos were exposed to aNF (0.1–2.5 lM) (A) alone or (B) in combination
with FICZ (10 nM). (C) Embryos injected with Ahr2-MO were exposed to 0.5 lM aNF (A0.5), 10 nM FICZ (F10) or the combination of aNF and FICZ. All data were normalized to
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statistical differences among groups were determined by One-way ANOVA followed by Dunnett’s test. Results in (C) is from a one experiment (n = 3) and statistical
differences between non-injected and Ahr2-MO injected groups at the same exposure were determined by Student’s t test. Statistically significant differences are indicated by
asterisks (⁄p < 0.05, ⁄⁄p < 0.01, and ⁄⁄⁄p < 0.001).
E. Wincent et al. / Biochemical Pharmacology 110–111 (2016) 117–129 125was examined at times up to 48 hpt (Fig. 6). To determine if the
observed effects were Ahr2-dependent, similar exposures were
performed with Ahr2-MO-injected embryos.
3.4.1. Mortality and phenotypic effects
Exposure to DMSO, FICZ or 0.1 or 0.5 lM aNF alone did not
cause any mortality or significant increase in phenotypic deformi-
ties (Fig. 5C and D). At a 1 lM dose, aNF caused a low incidence of
edema (10%) and a greater incidence of non-inflated swim bladder
(65%) than what appeared in the DMSO control (Fig. 5D). In con-
trast, numerous adverse effects were observed after the combined
exposures to FICZ and aNF, including pericardial- and yolk sac
edema, lack of swim bladder inflation, craniofacial malformations,
reduced eye size, body curvature, retarded growth and tube-
shaped heart (Fig. 5A and B).
The combination of FICZ with 1 lM aNF caused 88–100% mor-
tality with the three highest doses of FICZ (0.1, 1.0, and 10 nM)
while a lower mortality (32% and 8%) was observed after co-
exposure to 0.01 and 0.005 nM FICZ, respectively (Fig. 5E). After
exposure to FICZ combined with 1 lM aNF the incidence of mor-
tality was higher than the control in all but the group exposed to
the lowest concentration of FICZ (0.005 nM), and at all FICZ con-
centrations except this one all remaining live embryos had edema.
The combined exposure to FICZ and 0.5 lM aNF resulted in an
increase in mortality only with the highest FICZ concentration
(10 nM; 52%), while the lower FICZ concentrations (0.01–1 nM)
caused an increased edema but no mortality (Fig. 5E). LC50 values
for FICZ in combination with 1.0 lM or 0.5 lM aNF calculated from
the concentration–response data included in Fig. 6 were around 50times higher with the lower aNF concentration than with the
higher aNF concentration (9.8 and 0.02 nM FICZ, respectively),
showing that aNF sensitized embryos to FICZ.
To determine if the observed toxicity from combined treatment
with FICZ + aNF is Ahr2-dependent, embryos injected with Ahr2-
MO were exposed to 10 nM FICZ or 1 lM aNF alone or in combina-
tion. As seen in Fig. 5F, Ahr2 knockdown reduced the mortality
caused by co-exposure to 10 nM FICZ and 1 lM aNF to 31%, com-
pared to 100% mortality observed in the NI group exposed to these
two compounds; however, all live embryos displayed edema. Nota-
bly, the high incidence of non-inflated swim bladders observed
with embryos exposed to 1 lM aNF alone was not reduced upon
Ahr2-MO injection. Ctrl-MO embryos included for comparison
showed no difference compared to NI embryos for any of the expo-
sures (not shown).
3.4.2. Transcriptional effects
Zebrafish embryos were exposed to aNF or FICZ separately or in
combination as above. Exposure to aNF alone caused an increase in
CYP1A expression in a time- and dose-dependent manner; at
24 hpt all aNF concentrations had induced CYP1A to about 30-
fold the DMSO control (Fig. 6A). Exposure to FICZ resulted in a tran-
sient induction of CYP1A expression with highest level, 280-times
the DMSO control, after 6 h of treatment, which was followed by
a time-dependent reduction in expression (Fig. 6B).
Co-exposure to FICZ and 0.1–2.5 lM aNF resulted in a dose- and
time-dependent enhanced CYP1A expression. To investigate if
these effects were more-than additive (synergistic) we performed
statistical analysis of the observed CYP1A mRNA levels after co-
Table 2
Statistical analysis of CYP1A expression after combined exposure to FICZ and aNF.
hpt FICZ aNF 0.1 lM aNF 0.5 lM aNF 2.5 lM
Observed Observed Observed Observed
6 279 ± 25 15 ± 7 17 ± 5 7 ± 2
24 163 ± 30 32 ± 5 27 ± 2 27 ± 2
48 13 ± 2 6 ± 3 27 ± 6 12 ± 3
hpt FICZ + aNF 0.1 lM FICZ + aNF 0.5 lM FICZ + aNF 2.5 lM
Observed Calculated p valuea Observed Calculated p value Observed Calculated p value
6 298 ± 68 294 ± 26 0.9387 898 ± 142 296 ± 26 0.0019 1379 ± 43 286 ± 26 <0.0001
24 189 ± 19 195 ± 30 0.8027 534 ± 131 190 ± 29 0.0115 1413 ± 207 189 ± 30 0.0005
48 31 ± 4 19 ± 3 0.0152 163 ± 43 40 ± 6 0.0085 All embryos dead –
a p values of differences between observed CYP1A mRNA levels after co-exposure to FICZ with aNF and calculated sum of CYP1A mRNA levels after exposure to FICZ alone
+ aNF alone were determined by Student’s t test followed by Holm–Sidak post hoc test. Observed and calculated values are based on one experiment (n = 3) and given as
mean ± SD. CYP1A expression is given as relative levels compared to DMSO control at each respective time point. p values showing significant more-than additive values
(synergistic; p value < 0.05) are shown in bold font.
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CYP1A mRNA levels after exposure to FICZ alone and aNF alone
(Table 2). The level of CYP1A expression in embryos co-exposed
to FICZ and 0.1 lM aNF did not differ from that in the group
exposed to FICZ alone at 6 or 24 hpt but was increased to more
than additive levels at 48 hpt (Fig. 6B and Table 2). Co-exposure
to FICZ and 0.5 or 2.5 lM aNF strongly enhanced CYP1A expression
up to 5 and 9 times the level induced by FICZ alone at 6 and 24 hpt,
respectively, resulting in more-than additive CYP1A expression
levels (Table 2). At 48 hpt CYP1A expression in response to FICZ
+ 0.5 lM aNF was much lower than at 24 hpt, but still 12 times
higher compared to FICZ alone (Fig. 6B and Table 2), and all
embryos exposed to FICZ + 2.5 lM aNF were dead. This means that
the effect of FICZ in combination with aNF is synergistic.
To determine if the observed effects on CYP1A expression were
Ahr2-dependent, Ahr2-MO-injected embryos were exposed to FICZ
(10 nM) or aNF (0.5 lM) alone or in combination and compared to
non-injected embryos. The levels of CYP1A expression observed
with aNF or FICZ alone were significantly lower in the Ahr2-MO-
injected embryos as compared to NI embryos at all time-points
(Fig. 6C). In a similar manner, the synergistic induction of CYP1A
expression observed with the combined exposure to FICZ and
aNF was significantly reduced in the Ahr2-MO-injected embryos
at 6 and 24 hpt. At 48 hpt the CYP1A transcript levels in Ahr2-MO
embryos did not differ from those in the non-injected embryos.3.5. Levels of FICZ in embryos injected with CYP1A-MO or co-exposed
to aNF
To test whether morpholino-mediated knockdown of CYP1A or
co-exposure to aNF affects the level of FICZ in the embryos over
time we performed chemical analysis of embryos exposed to FICZ
using HPLC.3.5.1. CYP1-MO injected embryos
Zebrafish embryos injected with CYP1A-MO or CT-MO were
exposed to 10 nM FICZ starting at 24 hpf. Samples were taken at
5, 10, 24, and 48 hpt, extracted and analyzed for levels of FICZ
(Fig. 7A). Levels of FICZ in CT-MO injected embryos showed a weak
increase in level of FICZ from 37 to 44 fmol/embryo from 5 to
24 hpt, whereas a decrease to 33 fmol/embryo was observed at
48 hpt. CYP1A knockdown resulted in higher levels of FICZ at all
time points, with strongest effect observed at 48 hpt (33 and
73 fmol/embryo for Ctrl-MO and CYP1A-MO injected embryos,
respectively).3.5.2. Co-exposure to aNF
Zebrafish embryos (non-injected) were exposed to 10 nM FICZ
alone or to FICZ in combination with 0.5 lM or 1.0 lM aNF starting
at 24 hpf. Samples were taken at 5, 10, and 24 hpt, extracted and
analyzed for levels of FICZ (Fig. 7B). In combination with 0.5 lM
aNF, higher levels of FICZ were observed at 5 and 10 hpt; 33 and
40 fmol/embryo with FICZ alone compared to 66 and 71 fmol/
embryo in embryos co-exposed to aNF. Similar effects were
observed at 5 and 10 hpt after co-exposure to 1.0 lM aNF. This
embryo group showed higher levels of FICZ also at 24 hpt (43
and 54 fmol/embryo, respectively).4. Discussion
In this study we show that in zebrafish embryos, Ahr2 activa-
tion by FICZ was enhanced by interference with CYP1A expression
or function, resulting in Ahr2-dependent toxicity. Thus, mor-
pholino knockdown of CYP1A strongly increased the mortality,
pericardial edema and circulation failure caused by the endoge-
nous Ahr agonist FICZ, while the knockdown of Ahr2 strongly
reduced the toxicity resulting from exposure of CYP1A-MO-
injected embryos to FICZ. Several studies have indicated a role
for CYP1A1 in feedback-regulation of AHR signaling in mammals
and suggest that this feedback mechanism is essential for the
E. Wincent et al. / Biochemical Pharmacology 110–111 (2016) 117–129 127appropriate timing, duration, and amplitude of AHR-regulated cel-
lular functions [13,34]. In this context, elevated systemic levels of
endogenous, rapidly metabolized AHR ligands such as FICZ could
result from reduced catalytic activity of CYP1 enzymes, which
may contribute to adverse biological effects of potent CYP1 inhibit-
ing agents [35,36]. In support of this, morpholino-mediated knock-
down of CYP1A as well as co-exposure to the potent CYP1A/
CYP1B1 inhibitor aNF was shown to increase the levels of FICZ in
the zebrafish embryos (Fig. 7). In the present study, CYP1A knock-
down alone also resulted in an increased CYP1A expression, possi-
bly revealing the presence of endogenous AHR activators
dependent on CYP1 for metabolic clearance. Concomitant Ahr2
knockdown significantly reduced the increase in CYP1A expression
in the CYP1A-MO-injected embryos, confirming an increased Ahr2
activation upon CYP1A knockdown. This is consistent with the
hypothesis that a CYP1/AHR feedback system is crucial for regula-
tion of endogenous AHR signaling.
We also observed a somewhat increased toxicity by CYP1A knock-
down alone, an effect that has not been reported in previous zebra-
fish embryo studies [30,37]. A possible explanation for this could
be the use of different zebrafish strains; in our study the TL strain
was used whereas previous work has used the AB strain. However,
the toxicity observed in CYP1A-MO injected embryos was not clearly
reversed by Ahr2 knockdown and thus Ahr2-independent toxicity or
nonspecific toxicity by the morpholino (i.e. toxicity not related to the
CYP1A knockdown) cannot be ruled out.
The greater toxicity of chlorinated dioxins in comparison to FICZ
and other readily metabolized compounds is considered to depend
on the resistance of many chlorinated dioxins to degradation, lead-
ing to sustained AHR activation [38,39]. Recently, effects of FICZ on
mice administered the compound continuously via a micro-
osmotic pump were investigated by comparing host responses to
infection in cyp1a1 knockout (cyp1a1/) and wild type animals
[40]. In the cyp1a1/ mice continuous exposure to FICZ provoked
a response similar to that caused by TCDD, whereas continuous
FICZ exposure had no effect on wild type mice. Together with the
results from the FICZ replenishment- and CYP1A-knockdown
experiments presented in our study, these data suggest that a func-
tioning CYP1 biotransformation capacity is critical for controlling
the toxic effects of FICZ and possibly other labile AHR agonists [41].
TCDD-mediated hyper activation of AHR during embryogenesis
leads to embryonic lethality or severe developmental defects in
multiple tissues in zebrafish [42]. The molecular mechanisms
mediating these effects are still elusive; however, AHR-mediated
transcriptional regulation is believed to be crucial for these effects
[31]. In the present study, knockdown of Ahr2 strongly reduced the
mortality, pericardial edema and circulatory failure observed after
exposure to FICZ in CYP1A-MO embryos, indicating that the
observed toxicity is at least partly Ahr2-dependent. This was fur-
ther corroborated by the reduction of CYP1A expression at 6 and
24 hpt in the CYP1A/Ahr2-MO embryos exposed to FICZ, compared
to embryos injected only with CYP1A-MO and then exposed to
FICZ. The increased CYP1A expression observed at 48 hpt in the
combined CYP1A/Ahr2-MO group may be due to reduced Ahr2-
MO efficacy over time in combination with accumulation of
endogenous Ahr2 ligand(s) as a result of the CYP1A loss of function.
CYP1 enzymes have an established role in bioactivation of pro-
carcinogens as well as in the metabolism of endogenous com-
pounds; thus, induction of CYP1 enzyme activity is a possible
contributor to some toxic responses. However, there are several
studies suggesting that CYP1A induction is not linked to overt tox-
icity [35,43]. The role of CYP1A in AHR-related toxicity is contro-
versial, perhaps in part because different types of effects and
effects of different types of substrates are often conflated. Some
reports show that induction of CYP1A is a factor mediating toxicity,
and more specifically vascular toxicity by TCDD [30,44]. Sucheffects could involve reactive oxygen species generated by CYP1s
resulting from binding of the planar halogenated compound TCDD
[30,44]. Similarly, the knockout of CYP1A1 protected male mice
against toxicity of TCDD [45]. However, other reports show no pro-
tective role of CYP1A against systemic toxicity of TCDD [37,46,47].
With PAH substrates, on the other hand, there are several reports
demonstrating synergistic AHR-mediated toxicity with CYP1A
knockdown or exposure to a CYP1-inhibiting PAH in combination
with an AHR agonist [28,41,47–52].
The findings of enhanced PAH toxicity when in combination
with a CYP1A inhibitor suggests that such inhibition may enhance
the half-life of toxic PAHs [53]. However, less is known about
exogenous inhibitors of CYP1A in combination with natural or
endogenous ligands and AHR activators such as FICZ. In this study,
aNF was chosen as a chemical CYP1 inhibitor [24,54]. Co-exposure
to aNF and FICZ resulted in synergistic Ahr2 activation, as mea-
sured by altered CYP1A gene expression (Table 2) and potentiated
toxicity of FICZ. Notably, a doubling of the aNF concentration from
0.5 lM to 1 lM lowered the LC50 of FICZ by 500 times. The aNF
dose-dependent differences likely result from more efficient inhi-
bition of CYP1A activity at the higher dose, but may also involve
the metabolism [55] and thus a changing internal dose of aNF,
and the action of aNF as a partial agonist of Ahr (see below). The
phenotypic effects observed with exposure to FICZ + aNF are those
associated with classical AHR-mediated toxicity (e.g. bent spine,
craniofacial deformities, tube-shaped heart, etc). These effects
were at least partly Ahr2-dependent since knockdown of Ahr2
reduced both the toxicity and transcriptional effects. The lack of
complete rescue is most likely explained by a less than 100% effi-
cacy of the Ahr2-MO in combination with a highly toxic dose of
the FICZ/aNF combination.
The structural diversity of compounds shown to activate AHR
signaling raises the question whether all activators are bona fide
receptor ligands, or if they may activate through other mechanisms
such as the indirect activation through CYP1-inhibition as previ-
ously suggested by us [23]. Such a CYP1-inhibition mediated acti-
vation in vivo is supported by data on induced AHR signaling in
tissues from cyp1-triple KO mice [13], and by the induced Ahr2 sig-
naling observed in the CYP1A-MO-injected embryos reported in
the present study. Some compounds may act through several
mechanisms of AHR activation. aNF, for example, is considered a
weak AHR agonist and partial AHR antagonist [25–27] in addition
to being a potent CYP1 inhibitor. In this context, aNF may activate
the AHR both as a CYP1-inhibitor and a receptor agonist, depend-
ing on the concentration. While its function as a weak agonist
could explain the induction of CYP1A expression observed with
aNF alone, our recent studies using human cell lines suggest that
the AHR-activating capacity of aNF is rather mediated through
its role as a CYP1 inhibitor and subsequent accumulation of AHR
ligands [14,23]. Previous studies have confirmed the CYP1 inhibit-
ing effects of aNF in zebrafish embryos [47]. However we cannot
conclude that the observed toxicity is solely due to blocked CYP1
function and thereby blocked metabolism of FICZ. While co-
exposure to aNF was shown to increase the level of FICZ in the zeb-
rafish embryos, the relatively large increase in FICZ levels after co-
exposure to aNF as compared to that in CYP1A-MO injected
embryos suggests that aNF is either more effective in blocking FICZ
metabolism (e.g. by blocking both CYP1A and activity of other
CYP1 enzymes) or that aNF may also increase the uptake of FICZ.
Analysis of the rates of FICZ metabolism by the multiple zebrafish
CYP1s may help to clarify this. Further, other studies have demon-
strated that aNF can, for example, inhibit peroxidase activity [56],
repress p38MAPK signaling pathway [57] and inhibit aromatase
(CYP19) activity [58]. Whether such ‘‘off-target” effects or crosstalk
with other signaling pathways contribute to the toxicity observed
in our study is yet to be determined.
128 E. Wincent et al. / Biochemical Pharmacology 110–111 (2016) 117–129Thus, the mechanism by which a chemical may activate AHR
signaling will depend on qualities of the compound, the biological
dose, and the cell type, since cells differ in AHR inducibility and
metabolic capacity.
In conclusion, our data confirm the hypothesis that CYP1
enzymes are important for regulating systemic levels and biologi-
cal effects of FICZ in vivo, and further support the suggestion that
CYP1 inhibitors may contribute to AHR-mediated toxicity by dis-
rupting CYP1-dependent feedback regulation of endogenous AHR
agonists, causing prolonged and/or reinforced receptor activation.
The list of known CYP1 inhibitors is extensive, ranging from com-
mon environmental pollutants such as PAHs and PCBs, pharmaceu-
tical drugs such as ketoconazole, to bacterial endotoxins (e.g. LPS)
and physical agents (e.g. hypoxia and UV radiation). Considering
the combined everyday exposure to AHR activators (diet, pollu-
tants, and endogenous ligands) and CYP1 inhibitors, this points
to a mode of toxic action previously not accounted for.Funding
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